

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: CUTLER-06326

Serial No.: 09/899,412

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Neal R. Cutler

Filing Date: 07/05/01

Group Art Unit: 1615

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | Serial / Patent Number | Issue Date | Applicant / Patentee | Class | Subclass | Filing Date |
|----------------------|-------------|---------------------------|------------|-------------------------|-------|----------|-------------|
| RMG | 1 | 4,389,393 | 6/21/83 | Schor <i>et al.</i> | 424 | 19 | 3/26/82 |
| | 2 | 4,650,810 | 3/17/87 | Bays <i>et al.</i> | 514 | 415 | 1/26/83 |
| | 3 | 4,914,125 | 4/03/90 | Baldinger <i>et al.</i> | 514 | 520 | 7/06/89 |
| | 4 | 4,916,125 | 4/10/90 | Herrling <i>et al.</i> | 514 | 89 | 7/11/89 |
| | 5 | 4,933,367 | 6/12/90 | Wolff <i>et al.</i> | 514 | 570 | 7/10/86 |
| | 6 | 4,963,367 | 10/16/90 | Ecanow | 424 | 485 | 12/15/87 |
| | 7 | 4,994,483 | 2/19/91 | Oxford <i>et al.</i> | 514 | 415 | 11/30/89 |
| | 8 | 5,006,342 | 4/09/91 | Cleary <i>et al.</i> | 424 | 445 | 2/10/89 |
| | 9 | 5,021,428 | 6/04/91 | Carr <i>et al.</i> | 514 | 317 | 11/17/89 |
| | 10 | 5,051,426 | 9/24/91 | Parnell | 514 | 263 | 3/27/90 |
| | 11 | 5,200,413 | 4/06/93 | King <i>et al.</i> | 514 | 299 | 8/05/91 |
| | 12 | 5,242,949 | 9/07/93 | Goldberg <i>et al.</i> | 514 | 652 | 3/13/92 |
| | 13 | 5,248,684 | 9/28/93 | Suzuki <i>et al.</i> | 514 | 299 | 5/21/91 |
| | 14 | 5,273,759 | 12/28/93 | Simmons | 424 | 465 | 9/17/92 |
| | 15 | 5,288,498 | 2/22/94 | Stanley <i>et al.</i> | 424 | 440 | 9/05/89 |
| | 16 | 5,317,103 | 5/31/94 | Baker <i>et al.</i> | 544 | 367 | 7/16/92 |
| | 17 | 5,364,863 | 11/15/94 | Cohen <i>et al.</i> | 514 | 304 | 4/26/93 |
| | 18 | 5,399,574 | 3/21/95 | Robertson <i>et al.</i> | 514 | 339 | 6/06/91 |
| | 19 | 5,434,154 | 7/18/95 | Smith <i>et al.</i> | 514 | 249 | 4/26/94 |
| | 20 | 5,441,969 | 8/15/95 | Axelsson <i>et al.</i> | 514 | 338 | 12/22/93 |
| | 21 | 5,464,864 | 11/07/95 | King <i>et al.</i> | 514 | 468 | 6/17/92 |
| | 22 | 5,466,699 | 11/14/95 | Robertson <i>et al.</i> | 514 | 323 | 12/05/94 |
| | 23 | 5,468,768 | 11/21/95 | Cipollina <i>et al.</i> | 514 | 415 | 1/06/94 |
| | 24 | 5,487,898 | 1/30/96 | Lu <i>et al.</i> | 424 | 435 | 2/07/94 |
| | 25 | 5,491,148 | 2/13/96 | Berger <i>et al.</i> | 514 | 305 | 4/26/91 |
| | 26 | 5,494,910 | 2/27/96 | North <i>et al.</i> | 514 | 233.5 | 10/14/93 |
| | 27 | 5,637,611 | 6/10/97 | King <i>et al.</i> | 514 | 468 | 5/15/95 |
| | 28 | 5,672,356 | 9/30/97 | Rault <i>et al.</i> | 424 | 468 | 9/21/94 |
| | 29 | 5,855,907 | 1/05/99 | Peyman | 424 | 434 | 3/24/97 |
| | 30 | 5,877,183 | 3/02/99 | Cincotta | 514 | 288 | 6/06/97 |
| | 31 | 5,891,885 | 4/06/99 | Caruso | 514 | 289 | 10/24/96 |
| | 32 | 5,939,425 | 8/17/99 | Caruso | 514 | 289 | 5/19/97 |
| | 33 | 5,942,251 | 8/24/99 | Merkus | 424 | 493 | 4/17/98 |

Examiner:

Date Considered:

10/23/03

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: CUTLER-06326

Serial No.: 09/899,412

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: Neal R. Cutler

Filing Date: 07/05/01

Group Art Unit: 1615

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | Serial / Patent Number | Issue Date | Applicant / Patentee | Class | Subclass | Filing Date |
|-------------------|----------|------------------------|------------|-------------------------|-------|----------|-------------|
| RMG | 34 | 5,955,502 | 9/21/99 | Hansen <i>et al.</i> | 514 | 558 | 3/27/97 |
| | 35 | 6,010,719 | 1/04/00 | Remon <i>et al.</i> | 424 | 464 | 10/16/97 |
| | 36 | 6,077,539 | 6/20/00 | Plachetka <i>et al.</i> | 424 | 474 | 11/10/97 |
| | 37 | 6,103,218 | 8/15/00 | Brucker <i>et al.</i> | 424 | 45 | 4/23/97 |
| | 38 | 6,139,819 | 10/31/00 | Unger <i>et al.</i> | 424 | 9.52 | 10/17/97 |
| | 39 | 6,197,331 | 3/06/01 | Lerner <i>et al.</i> | 424 | 448 | 7/24/97 |
| | 40 | 6,200,604 | 3/13/01 | Pather <i>et al.</i> | 424 | 466 | 6/08/99 |
| RMG | 41 | 6,221,392 | 4/24/01 | Khankari <i>et al.</i> | 424 | 464 | 12/16/99 |

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

| | | |
|-----|----|---|
| RMG | 42 | Goodman and Gilman's "The Pharmaceutical Basis of Therapeutics", 8th ed., McGraw-Hill, Inc. (1990), pp. 944-947 |
| | 43 | Becker, "Migraine-associated symptoms: Clinical significance and management," <i>Can J Clin Pharmacol</i> 6 (Suppl A):15A-19A (1999) |
| | 44 | Kiechel, "The Bioavailability and Kinetics of Dihydroergotamine" in Fitacha (Ed.); <i>Neuester Scand Der Dihydrergot Forschung</i> . Stuttgart Georg Thiema: 32-46 (1984) |
| | 45 | Migranal (dihydroergotamine mesylate, USP) Nasal Spray Information, Novartis Pharmaceuticals Company, Inc. Publication 30721901, 1997 |
| RMG | 46 | D.H.E. 45 (dihydroergotamine mesylate) Injection, USP Information, Novartis Pharmaceuticals Company, Inc., Publication 30220906, 1998 |
| | 47 | |
| | 48 | |
| | 49 | |
| | 50 | |
| | 51 | |
| | 52 | |
| | 53 | |
| | 54 | |
| | 55 | |
| | 56 | |
| | 57 | |
| | 58 | |
| | 59 | |
| | 60 | |
| | 61 | |
| | 62 | |

Examiner:

Date Considered:

10/23/03

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.